Investors back Infinity stock offer on new early data, surging PI3K interest
This article was originally published in Scrip
With only early-stage data in hand for its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma IPI-145, Infinity Pharmaceuticals' recent $150 million common stock offering and response to preliminary Phase I results in hematological malignancies seems to reflect enthusiasm for PI3K inhibitors as a class - although the company says its findings so far show that it may have a class-leading therapeutic candidate.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.